Company Overview
Viridian Therapeutics, Inc. engages in the discovery, development, and commercialization of treatments designed for serious and rare diseases, with a specific focus on IGF-1R therapies for conditions such as thyroid eye disease. The company operates within the Healthcare sector and is classified specifically under the Biotechnology industry, a classification that signifies its reliance on research and development to generate future revenue streams rather than current product sales. The firm employs a workforce of 252 individuals and holds a market capitalization of $2.85B, which positions it as a significant entity within the biotechnology landscape despite its stage of development. Its annual revenue stands at $70.85M, indicating that the company has achieved substantial commercial traction, while the market cap relative to this revenue figure suggests that the market is pricing in significant future growth potential and valuation expectations rather than current cash flows.
Financial Health
The company reported a revenue of $70.85M for the trailing twelve months, yet it recorded a net income of $-281,928,000 and an EBITDA of $-362,935,008, revealing a substantial gap between top-line sales and bottom-line profitability. This significant disparity between revenue and net income highlights a cost structure dominated by heavy research and development expenditures and operational losses typical of early-to-mid-stage biotechnology firms. The free cash flow stands at $-162,068,368, which indicates that the company is currently burning cash to fund its operations and pipeline advancement rather than generating surplus liquidity from its business activities. Despite the negative cash flow, the company maintains a cash balance of $874.65M, providing a substantial runway to support ongoing development without immediate need for capital raises. The margins reflect the company's current operational phase, with a gross margin of 0.0%, an operating margin of -95643.2%, and a profit margin of 0.0%, all of which underscore the high burn rate and lack of profitability inherent in developing novel therapeutic antibodies like Veligrotrug. On the liability side, the company carries $52.59M in debt against its cash reserves, resulting in a debt-to-equity ratio of 7.28, which suggests a leveraged balance sheet structure where equity financing is the primary source of capital. However, the current ratio is 12.65, a metric that indicates an extremely strong short-term liquidity position, suggesting the company has more than enough current assets to cover its current liabilities. Return on equity is recorded at -49.2% and return on assets at -27.7%, metrics that reveal that management effectiveness is currently measured by the ability to manage resources efficiently during a loss-making phase rather than by generating positive returns.
Valuation Assessment
Valuation metrics for the company present a complex picture due to its lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -13.59. The negative forward P/E implies that earnings are expected to remain negative in the near term, meaning traditional price-to-earnings models are not applicable for assessing immediate value. The price-to-book ratio is 4.80, which indicates that the market is valuing the company at nearly five times its book value, suggesting a significant market premium assigned to its intangible assets and future drug potential. Alternative valuation metrics further illustrate this premium, with a price-to-sales ratio of 40.16 and an EV/EBITDA of -5.94, both of which suggest the market is pricing the stock based on future commercialization prospects rather than current financial performance. Regarding price momentum, the 52-week high is $34.29 and the 52-week low is $9.90, placing the current trading price within a range that reflects high volatility and significant swing from recent highs. The beta value is 1.01, which indicates that the stock's price volatility mirrors the broader market, meaning it does not exhibit significantly higher or lower systemic risk compared to the general market index.
Growth & Income
The company demonstrated a revenue growth of 83.3% year-over-year, while earnings growth is N/A due to the absence of positive net income. This dynamic, where revenue expands rapidly but earnings remain negative, implies that the company is successfully scaling its sales and market penetration while still incurring heavy costs associated with clinical trials and manufacturing. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm reinvests all available earnings back into the business to accelerate growth and development of its therapy pipeline. The overall growth and income profile is characterized by aggressive top-line expansion funded by internal cash reserves and external financing, with no distribution of income to shareholders at this stage of the company's lifecycle.